Chris Fegan

22.9k total citations
161 papers, 6.2k citations indexed

About

Chris Fegan is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Chris Fegan has authored 161 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Genetics, 51 papers in Pathology and Forensic Medicine and 49 papers in Immunology. Recurrent topics in Chris Fegan's work include Chronic Lymphocytic Leukemia Research (105 papers), Lymphoma Diagnosis and Treatment (51 papers) and Immunodeficiency and Autoimmune Disorders (30 papers). Chris Fegan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (105 papers), Lymphoma Diagnosis and Treatment (51 papers) and Immunodeficiency and Autoimmune Disorders (30 papers). Chris Fegan collaborates with scholars based in United Kingdom, United States and France. Chris Fegan's co-authors include Chris Pepper, Donald Milligan, Paul Moss, Guy Pratt, Suparno Chakrabarti, Paul Brennan, Peter Hillmen, Tatjana Stanković, Jane Starczynski and Husam Osman and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Chris Fegan

161 papers receiving 6.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Chris Fegan 2.7k 2.0k 1.9k 1.6k 1.5k 161 6.2k
Marinus H. J. van Oers 2.4k 0.9× 3.2k 1.6× 2.8k 1.5× 1.9k 1.2× 2.8k 1.9× 175 9.0k
Renato Zambello 2.2k 0.8× 3.9k 1.9× 2.0k 1.1× 1.6k 1.0× 2.0k 1.4× 288 8.0k
Livio Trentin 2.4k 0.9× 3.6k 1.8× 2.5k 1.3× 1.8k 1.2× 1.9k 1.3× 332 8.6k
Georg Heß 1.4k 0.5× 1.2k 0.6× 2.1k 1.1× 1.1k 0.7× 2.2k 1.5× 192 6.6k
Andrew Grigg 3.8k 1.4× 1.2k 0.6× 1.7k 0.9× 1.3k 0.8× 2.2k 1.5× 274 8.8k
Renato Fanin 1.4k 0.5× 1.2k 0.6× 1.3k 0.7× 1.4k 0.9× 2.0k 1.4× 226 6.6k
Bruno Varet 2.6k 1.0× 1.4k 0.7× 1.1k 0.6× 1.7k 1.1× 1.4k 1.0× 145 7.6k
Jiřı́ Mayer 4.7k 1.7× 1.4k 0.7× 2.6k 1.4× 1.6k 1.1× 1.7k 1.1× 421 8.7k
Anna Dmoszyńska 2.7k 1.0× 1.7k 0.9× 2.0k 1.1× 2.9k 1.9× 3.0k 2.0× 207 8.0k
Gösta Gahrton 2.3k 0.8× 2.1k 1.1× 1.3k 0.7× 2.6k 1.7× 2.2k 1.5× 268 8.3k

Countries citing papers authored by Chris Fegan

Since Specialization
Citations

This map shows the geographic impact of Chris Fegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Fegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Fegan more than expected).

Fields of papers citing papers by Chris Fegan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Fegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Fegan. The network helps show where Chris Fegan may publish in the future.

Co-authorship network of co-authors of Chris Fegan

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Fegan. A scholar is included among the top collaborators of Chris Fegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Fegan. Chris Fegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ponsford, Mark, Kirsten Bentley, Jade Cole, et al.. (2022). Mechanically Ventilated Patients Shed High-Titer Live Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for Extended Periods From Both the Upper and Lower Respiratory Tract. Clinical Infectious Diseases. 75(1). e82–e88. 5 indexed citations
2.
Morschhauser, Franck, Martin J.S. Dyer, Harriet S. Walter, et al.. (2020). Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia. 35(7). 2108–2113. 13 indexed citations
3.
Danilov, Alexey V., Charles Herbaux, Harriet S. Walter, et al.. (2020). Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(12). 2810–2818. 47 indexed citations
4.
O’Donnell, Valerie B., David W. Thomas, Richard J. Stanton, et al.. (2020). Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function. 1(1). zqaa002–zqaa002. 106 indexed citations
5.
Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations
6.
Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations
7.
Munir, Talha, Andy C. Rawstron, Kristian Brock, et al.. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. British Journal of Haematology. 181. 34–35. 1 indexed citations
8.
9.
Wong, Ryan, Chris Pepper, Paul Brennan, et al.. (2013). Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 98(12). 1930–1938. 69 indexed citations
10.
Oscier, David, Claire Dearden, Efrem Eren, et al.. (2012). Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology. 159(5). 541–564. 114 indexed citations
11.
12.
Miners, Kelly L., Garry Dolton, Chris Pepper, et al.. (2011). A Novel Tumor Antigen Derived from Enhanced Degradation of Bax Protein in Human Cancers. Cancer Research. 71(16). 5435–5444. 14 indexed citations
13.
Buggins, Andrea G.S., Chris Pepper, Piers Patten, et al.. (2010). Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF-κB Activation and De novo Gene Transcription. Cancer Research. 70(19). 7523–7533. 75 indexed citations
14.
Hartley, John A., Marie Suggitt, Zhizhi Chen, et al.. (2010). SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity. Cancer Research. 70(17). 6849–6858. 43 indexed citations
15.
Darvall, Katy, Rachel Sam, D.J. Adam, et al.. (2010). The Incidence of Raised Procoagulant Factors and Hyperhomocysteinaemia in Chinese Patients with Chronic Venous Insufficiency. European Journal of Vascular and Endovascular Surgery. 40(2). 260–266. 3 indexed citations
16.
Darvall, Katy, Rachel Sam, Donald J. Adam, et al.. (2009). Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. Journal of Vascular Surgery. 49(5). 1235–1241. 43 indexed citations
17.
Hobbs, S.D., et al.. (2007). The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms. Journal of Vascular Surgery. 46(4). 682–686. 12 indexed citations
18.
Hobbs, S.D., Tim Marshall, Chris Fegan, Donald J. Adam, & Andrew W. Bradbury. (2006). The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty. Journal of Vascular Surgery. 43(1). 40–46. 33 indexed citations
19.
Burns, Philip A., Teun Wilmink, Chris Fegan, & Andrew W. Bradbury. (2003). Exercise in claudicants is accompanied by excessive thrombin generation. European Journal of Vascular and Endovascular Surgery. 26(2). 150–155. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marinus H. J. van Oers Breakdown of academic impact, for papers by Renato Zambello Breakdown of academic impact, for papers by Livio Trentin Breakdown of academic impact, for papers by Georg Heß Breakdown of academic impact, for papers by Andrew Grigg Breakdown of academic impact, for papers by Renato Fanin Breakdown of academic impact, for papers by Bruno Varet Breakdown of academic impact, for papers by Jiřı́ Mayer Breakdown of academic impact, for papers by Anna Dmoszyńska Breakdown of academic impact, for papers by Gösta Gahrton
Rankless by CCL
2026